Evidence map›Paper›PMID 42420257›Full record

ArticleBlood cancer journal2026

WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.

Maria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, Abigail L Peachey, Amanda Kofides, John Hatcher, Andres Ramirez Gamero, Alberto Guijosa, Guang Yang, Hao Sun and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Maria Luisa GuerreraBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0730-4678
Xia LiuBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Nickolas TsakmaklisBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Abigail L PeacheyBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Amanda KofidesBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
John HatcherBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Andres Ramirez GameroBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Alberto GuijosaBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Guang YangBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3049-4200
Hao SunBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Shirong LiuBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3821-9134
Christopher J PattersonBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Kirsten MeidBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Catherine FlynnBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Ruben D CarrascoHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6849-1852
Andrew R BranaganHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3868-9267
Shayna R SarosiekBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0075-6735
Jorge J CastilloBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9490-7532
Kenneth C AndersonHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6418-0886
Nikhil MunshiHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7344-9795
Steven P TreonBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA. steven_treon@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-6393-6154
Zachary R HunterBing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1689-1691

Funding

International Waldenstrom's Macroglobulinemia Foundation (International Waldenstrom's Macroglobulinemia Foundation, Inc.) Robert A. Kyle Career Development Award
6 · The paper itself

Abstract

WNK2 is a known tumor suppressor in a set of solid tumors, including glioblastoma multiforme and pancreatic ductal adenocarcinoma. WNK2 functions are largely unknown beyond the kinase domain (KD)-dependent inhibition of ERK1/2 signaling. Waldenström's Macroglobulinemia (WM) is an indolent, yet incurable, B cell lymphoma characterized by highly recurrent MYD88 (MYD88

Indexed as

MutationMyeloid Differentiation Factor 88Protein Serine-Threonine KinasesWaldenstrom MacroglobulinemiaCell Line, TumorGene Expression Regulation, NeoplasticHumansProtein IsoformsMYD88 protein, humanMyeloid Differentiation Factor 88Protein IsoformsProtein Serine-Threonine KinasesWNK2 protein, human

Identifiers

PMID42420257
PMCPMC13631340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.